 Kintara Therapeutics Inc NASDAQ:KTRA, the cancer-focused biopharma, said it has enough cash to fund its planned operations into the fourth quarter of calendar 2021, as the company posted its second-quarter results on Friday. Fiscal 2Q to end-December, 2020 was an important period of progress, said the company, which is advancing two late-stage, Phase 3-ready therapeutics - VAL-083 for glioblastoma multiforme GBM and REM-001 for cutaneous metastatic breast cancer CMBC. 